[
  {
    "ts": null,
    "headline": "Johnson & Johnson Temporarily Pulls New Treatment for Atrial Fibrillation to Probe Adverse Events",
    "summary": "Johnson & Johnson (JNJ) Wednesday said it paused the rollout of Varipulse cardiac device in the US e",
    "url": "https://finnhub.io/api/news?id=91dd8781c142731413984bbb892e96bfa47a353f2d0ffe716469362cc54cc4b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736369879,
      "headline": "Johnson & Johnson Temporarily Pulls New Treatment for Atrial Fibrillation to Probe Adverse Events",
      "id": 132334884,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) Wednesday said it paused the rollout of Varipulse cardiac device in the US e",
      "url": "https://finnhub.io/api/news?id=91dd8781c142731413984bbb892e96bfa47a353f2d0ffe716469362cc54cc4b2"
    }
  },
  {
    "ts": null,
    "headline": "J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product",
    "summary": "Johnson & Johnson stock skidded Wednesday after the company temporarily paused sales of its pulsed field ablation system.",
    "url": "https://finnhub.io/api/news?id=281f66352bc2508bc1d0f78680b30e0a197a098504556f9cd1500a74899969b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736361887,
      "headline": "J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product",
      "id": 132320074,
      "image": "",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson stock skidded Wednesday after the company temporarily paused sales of its pulsed field ablation system.",
      "url": "https://finnhub.io/api/news?id=281f66352bc2508bc1d0f78680b30e0a197a098504556f9cd1500a74899969b6"
    }
  },
  {
    "ts": null,
    "headline": "San Francisco Police Cancel Time Off as Healthcare Execs Descend",
    "summary": "San Francisco Police Cancel Time Off as Healthcare Execs Descend",
    "url": "https://finnhub.io/api/news?id=d4f134b550c3a8c60863a258cf152f37c683e7cc5e0cfc0352b9f34193782df9",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736357340,
      "headline": "San Francisco Police Cancel Time Off as Healthcare Execs Descend",
      "id": 132408145,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "San Francisco Police Cancel Time Off as Healthcare Execs Descend",
      "url": "https://finnhub.io/api/news?id=d4f134b550c3a8c60863a258cf152f37c683e7cc5e0cfc0352b9f34193782df9"
    }
  },
  {
    "ts": null,
    "headline": "J&J pauses Varipulse PFA cases in US",
    "summary": "The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for the pulsed field ablation system.",
    "url": "https://finnhub.io/api/news?id=91fdcba77d87dc71506b99b6b18cf06cf93cc0e3c912c3c3fc2a2d390851f5c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736350453,
      "headline": "J&J pauses Varipulse PFA cases in US",
      "id": 132334887,
      "image": "https://imgproxy.divecdn.com/oQtfWbmNlPp2NuUuH733vCIilvc73utmoIQII3iiMnc/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9WQVJJUFVMU0VfUGxhdGZvcm1fSW1hZ2VfMS5qcGc=.webp",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for the pulsed field ablation system.",
      "url": "https://finnhub.io/api/news?id=91fdcba77d87dc71506b99b6b18cf06cf93cc0e3c912c3c3fc2a2d390851f5c6"
    }
  },
  {
    "ts": null,
    "headline": "Inari Gets A Fair Bid As Stryker Buys Yet Another High-Growth Asset",
    "summary": "Stryker's acquisition of Inari for $4.9B enhances its neurovascular portfolio and boosts revenue growth by 50bp, with minimal dilution. Learn more on SYK stock here.",
    "url": "https://finnhub.io/api/news?id=87d0d384d748ad6d1bf599c10bc381505dc40cf6f51ed49e2b62d2fe67b84efb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736344771,
      "headline": "Inari Gets A Fair Bid As Stryker Buys Yet Another High-Growth Asset",
      "id": 132320000,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1297034305/image_1297034305.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Stryker's acquisition of Inari for $4.9B enhances its neurovascular portfolio and boosts revenue growth by 50bp, with minimal dilution. Learn more on SYK stock here.",
      "url": "https://finnhub.io/api/news?id=87d0d384d748ad6d1bf599c10bc381505dc40cf6f51ed49e2b62d2fe67b84efb"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights NVIDIA, Meta Platforms, Johnson & Johnson, Rave Restaurant and EVI Industries",
    "summary": "NVIDIA, Meta Platforms, Johnson & Johnson, Rave Restaurant and EVI Industries are part of the Zacks top Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=419b7599415b921c708d494ece2cb9281fdc98a704a3fcec25c6349be2fbf120",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736343720,
      "headline": "The Zacks Analyst Blog Highlights NVIDIA, Meta Platforms, Johnson & Johnson, Rave Restaurant and EVI Industries",
      "id": 132317239,
      "image": "https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "NVIDIA, Meta Platforms, Johnson & Johnson, Rave Restaurant and EVI Industries are part of the Zacks top Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=419b7599415b921c708d494ece2cb9281fdc98a704a3fcec25c6349be2fbf120"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease",
    "summary": "Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being investigated to treat patients with early Alzheimer's disease (AD) in the Phase 2b \"AuTonomy\" study. The internally discovered mAb has shown the potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid (CSF) from treated AD patients, and in blocking the development",
    "url": "https://finnhub.io/api/news?id=19f5528dfa411270faf9adb8ce0961dead688a282b89fdab9f22383e8ac8bc3b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736341200,
      "headline": "Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease",
      "id": 132316078,
      "image": "https://media.zenfs.com/en/prnewswire.com/ab83139242659d47a10c529ea6178420",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being investigated to treat patients with early Alzheimer's disease (AD) in the Phase 2b \"AuTonomy\" study. The internally discovered mAb has shown the potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid (CSF) from treated AD patients, and in blocking the development",
      "url": "https://finnhub.io/api/news?id=19f5528dfa411270faf9adb8ce0961dead688a282b89fdab9f22383e8ac8bc3b"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Johnson & Johnson (NYSE:JNJ) on Business Model Mastery Substack by The Antifragile Investor. In this article, we will summarize the bulls’ thesis on JNJ. Johnson & Johnson (NYSE:JNJ)’s share was trading at $146.23 as of Jan 7th. JNJ’s trailing and forward P/E were 24.17 and 13.76 respectively according to Yahoo […]",
    "url": "https://finnhub.io/api/news?id=08d9845f6be9c87ae25f9208d1ef6388c1ff6f98d006acedb9f6bde2008f62bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736341141,
      "headline": "Johnson & Johnson (JNJ): A Bull Case Theory",
      "id": 132316080,
      "image": "https://media.zenfs.com/en/insidermonkey.com/7c4f7ef6a0689d00a6beda19c61afebc",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Johnson & Johnson (NYSE:JNJ) on Business Model Mastery Substack by The Antifragile Investor. In this article, we will summarize the bulls’ thesis on JNJ. Johnson & Johnson (NYSE:JNJ)’s share was trading at $146.23 as of Jan 7th. JNJ’s trailing and forward P/E were 24.17 and 13.76 respectively according to Yahoo […]",
      "url": "https://finnhub.io/api/news?id=08d9845f6be9c87ae25f9208d1ef6388c1ff6f98d006acedb9f6bde2008f62bf"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Roundup: Why I Prefer Johnson & Johnson Over Pfizer",
    "summary": "Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to PFE's higher yield.",
    "url": "https://finnhub.io/api/news?id=1986a257e9418c131f9911f90840e9390e99618d70ad2b57bee4d8e33032fd0e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736338385,
      "headline": "Dividend Roundup: Why I Prefer Johnson & Johnson Over Pfizer",
      "id": 132318224,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1020814006/image_1020814006.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to PFE's higher yield.",
      "url": "https://finnhub.io/api/news?id=1986a257e9418c131f9911f90840e9390e99618d70ad2b57bee4d8e33032fd0e"
    }
  },
  {
    "ts": null,
    "headline": "J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial",
    "summary": "The Phase III MARIPOSA trial involved 1,074 subjects.",
    "url": "https://finnhub.io/api/news?id=a5949c4d6d1cf0f7c673d64c56ef3ad30cbe09f02c2f5409f93eef585403de13",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736333088,
      "headline": "J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial",
      "id": 132316082,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/22/2025/01/CTA-2-JNJ-Jnjshutterstock_2491940571.jpg",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Phase III MARIPOSA trial involved 1,074 subjects.",
      "url": "https://finnhub.io/api/news?id=a5949c4d6d1cf0f7c673d64c56ef3ad30cbe09f02c2f5409f93eef585403de13"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson - RYBREVANT plus LAZCLUZE shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib",
    "summary": "RARITAN - Johnson & Johnson today announced positive topline results for the gold standard endpoint in cancer treatment of overall survival from the Phase 3 MARIPOSA study, evaluating RYBREVANT plus...",
    "url": "https://finnhub.io/api/news?id=2cf7d81b0827fc425e6161be89c0a2a532653a954880d7c5aa5561233c152e68",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736330147,
      "headline": "Johnson & Johnson - RYBREVANT plus LAZCLUZE shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib",
      "id": 132315979,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "RARITAN - Johnson & Johnson today announced positive topline results for the gold standard endpoint in cancer treatment of overall survival from the Phase 3 MARIPOSA study, evaluating RYBREVANT plus...",
      "url": "https://finnhub.io/api/news?id=2cf7d81b0827fc425e6161be89c0a2a532653a954880d7c5aa5561233c152e68"
    }
  },
  {
    "ts": null,
    "headline": "Merck, Johnson & Johnson share losses lead Dow's 180-point fall",
    "summary": "Merck, Johnson & Johnson share losses lead Dow's 180-point fall",
    "url": "https://finnhub.io/api/news?id=ef134ca04be5aef37b93f3b9f9313f1385c8076a0ea8e4ff18d1315a70e3d0f3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736329980,
      "headline": "Merck, Johnson & Johnson share losses lead Dow's 180-point fall",
      "id": 132321867,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Merck, Johnson & Johnson share losses lead Dow's 180-point fall",
      "url": "https://finnhub.io/api/news?id=ef134ca04be5aef37b93f3b9f9313f1385c8076a0ea8e4ff18d1315a70e3d0f3"
    }
  },
  {
    "ts": null,
    "headline": "CURE: Analyst Estimates Point To Significant Gains In 2025",
    "summary": "The Direxion Daily Healthcare Bull 3X Shares ETF seeks to deliver 300% (3x) of the return of an index focused on large-cap US healthcare stocks.",
    "url": "https://finnhub.io/api/news?id=d511117d3542b3c924b27ade3e17e3d5a504a7d2af3c6fa8d68efe57e54c1850",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736327815,
      "headline": "CURE: Analyst Estimates Point To Significant Gains In 2025",
      "id": 132315626,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The Direxion Daily Healthcare Bull 3X Shares ETF seeks to deliver 300% (3x) of the return of an index focused on large-cap US healthcare stocks.",
      "url": "https://finnhub.io/api/news?id=d511117d3542b3c924b27ade3e17e3d5a504a7d2af3c6fa8d68efe57e54c1850"
    }
  },
  {
    "ts": null,
    "headline": "Latest Memo From Howard Marks: On Bubble Watch",
    "summary": "Latest Memo From Howard Marks: On Bubble Watch",
    "url": "https://finnhub.io/api/news?id=721228aa43a508c70829cd60339ce56e1dcc3fc8af69f7019e3e1686604113e0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736326800,
      "headline": "Latest Memo From Howard Marks: On Bubble Watch",
      "id": 132315523,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=721228aa43a508c70829cd60339ce56e1dcc3fc8af69f7019e3e1686604113e0"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Gets FDA Fast-Track Designation for Posdinemab in Alzheimer's",
    "summary": "By Colin Kellaher Johnson & Johnson on Wednesday said it has won Food and Drug Administration fast-track designation for its proposed posdinemab treatment for Alzheimer's disease. J&J is...",
    "url": "https://finnhub.io/api/news?id=8cc24272488dd94790e35fb70a95ede949aa54ddc1706f7b4d06ef6f096a3910",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736325729,
      "headline": "Johnson & Johnson Gets FDA Fast-Track Designation for Posdinemab in Alzheimer's",
      "id": 132315243,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Johnson & Johnson on Wednesday said it has won Food and Drug Administration fast-track designation for its proposed posdinemab treatment for Alzheimer's disease. J&J is...",
      "url": "https://finnhub.io/api/news?id=8cc24272488dd94790e35fb70a95ede949aa54ddc1706f7b4d06ef6f096a3910"
    }
  },
  {
    "ts": null,
    "headline": "J&J: positive ph.III results in lung cancer",
    "summary": "Johnson & Johnson announces positive results from a phase 3 study evaluating Rybrevant and Lazcluze as first-line treatment for EGFR-mutated non-small cell lung cancer . The chemotherapy-free regimen...",
    "url": "https://finnhub.io/api/news?id=af9a242426378c8adcc1e1610c02973e4763cd65d4db8e387fc5862659f61212",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736319371,
      "headline": "J&J: positive ph.III results in lung cancer",
      "id": 132314628,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announces positive results from a phase 3 study evaluating Rybrevant and Lazcluze as first-line treatment for EGFR-mutated non-small cell lung cancer . The chemotherapy-free regimen...",
      "url": "https://finnhub.io/api/news?id=af9a242426378c8adcc1e1610c02973e4763cd65d4db8e387fc5862659f61212"
    }
  },
  {
    "ts": null,
    "headline": "VOOV: S&P 500 Value Over Growth In 2025, Solid Macro Backdrop",
    "summary": "The Vanguard S&P 500 Value ETF (VOOV) is a strong choice for long-term investors in 2024, offering solid performance and growth potential. See more here.",
    "url": "https://finnhub.io/api/news?id=4a8e6341196e54e7655f86df2c02bdf13815f313c8ff8fd7981cadfb78fe6328",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736308907,
      "headline": "VOOV: S&P 500 Value Over Growth In 2025, Solid Macro Backdrop",
      "id": 132313081,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157338910/image_157338910.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The Vanguard S&P 500 Value ETF (VOOV) is a strong choice for long-term investors in 2024, offering solid performance and growth potential. See more here.",
      "url": "https://finnhub.io/api/news?id=4a8e6341196e54e7655f86df2c02bdf13815f313c8ff8fd7981cadfb78fe6328"
    }
  }
]